Patent intelligence · US
US 11007184
Cancer treatments using combinations of type 2 MEK and ERK inhibitors
Cancer treatments using combinations of type 2 MEK and ERK inhibitors
Patent details — US 11007184
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 18, 2021
- Expiration
- May 13, 2041
- Applicant
- Biomed Valley Discoveries, Inc.
- Claims
- 33
- CPC classes
- A61K, A61K31/337, A61K31/4184, A61K31/437
Quick answer
US 11007184 (Cancer treatments using combinations of type 2 MEK and ERK inhibitors) is held by Biomed Valley Discoveries, Inc.. Status: granted. Granted May 18, 2021. Expires May 13, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Biomed Valley Discoveries, Inc.
- Grant date
- Expiration
- Claims
- 33
- CPC classes
- A61K, A61K31/337, A61K31/4184, A61K31/437, A61K31/4439, A61K31/506
More from Biomed Valley Discoveries, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12427173
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
granted -
US 12428415
Matriptase 2 inhibitors and uses thereof
granted -
US 12421236
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
granted -
US 12420085
Synergistic therapies for inter vertebral disc degeneration
granted -
US 12421231
Azaindole derivatives and their use as ERK kinase inhibitors
granted -
US 12403069
Adapter for use in a planetary mixer
granted -
US 12398179
Nanomolar peptides and derivatives to differentially modulate ephrin receptors
granted -
US 12396924
Adapter for use in a planetary mixer
granted
Frequently asked questions
What is US patent 11007184?
US 11007184 (Cancer treatments using combinations of type 2 MEK and ERK inhibitors) is held by Biomed Valley Discoveries, Inc.. Status: granted. Granted May 18, 2021. Expires May 13, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11007184?
Biomed Valley Discoveries, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 706 pharmaceutical patents for this assignee.
When does US 11007184 expire?
Our index shows an expiration date of May 13, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.